Key facts
- Eclipse Regenesis’s last known valuation is $14.0M (Apr 2023).
- It has raised $9.3M; the latest was Later Stage VC in Aug 2025.
- Notable investors include US National Science Foundation, Impact Assets, MedTech Innovator, Atacama Ventures, MainSheet Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Eclipse Regenesis
- ·The full record, as it builds
Funding rounds
No funding rounds for Eclipse Regenesis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eclipse Regenesis
Developer of a therapeutic device designed to improve tissue regeneration therapy. The company's device specializes in the production of a restorative therapy that stimulates the growth of new intestine tissues thereby treating short bowel syndrome, enabling patients to address their nutrition malabsorption disorder caused by a lack of enough functional small intestine.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2017
- Employees
- 8
- Website
- eclipseregenesis.com/
- Ownership
- Privately Held (backing)
Eclipse Regenesis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eclipse Regenesis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eclipse Regenesis in its N-PORT filings yet. We sweep new filings monthly.